Pluristem Therapeutics Inc (PSTI)

[FDApproved]

64th ASH MEETING Monday, December 12, 2022, 6:00 PM-8:00 PM

#4686 PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Among patients who received blood transfusions at any time during follow up, a meaningful reduction in the mean number of transfused units per month, for both PLT and RBC transfusions, was observed as early as 3 months following PLX-R18 treatment and lasted throughout the 12-month follow up period. For PLT, the mean monthly number of transfused units dropped from 5.09 at baseline to 0.55 at 12 months (p<0.05); for RBC, from 2.91 at baseline to 0.00 at 12 months (p=0.0005).

Conclusion: PLX-R18 therapy appears to be safe and well tolerated and shows promise in improving incomplete hematopoietic recovery after HCT. Further clinical studies are warranted to optimize the efficacy of PLX-R18 in treatment of cytopenia in the post-HCT setting and expand the potential to other marrow failure disorders as well as cytopenia associated with certain treatment modalities such as CAR-T therapy.

https://ash.confex.com/ash/2022/webprogram/Paper169266.html